Nanolek Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 800

Employees

  • Latest Deal Type
  • M&A

Nanolek General Information

Description

Developer of a biopharmaceutical drugs intended to serve the Russian healthcare market. The company specializes in import-substituting medicines and vaccines, thereby helping in the prevention and treatment of whooping cough, diphtheria, tetanus, poliomyelitis, and diseases caused by Haemophilus influenzae type b.

Contact Information

Website
www.nanolek.ru
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Baker Plaza Business Center, 2nd floor, office 24
  • Butyrsky Val street Butyrsky Val, 68/70, building. 1
  • Moscow, 127055
  • Russia
+7 8
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Baker Plaza Business Center, 2nd floor, office 24
  • Butyrsky Val street Butyrsky Val, 68/70, building. 1
  • Moscow, 127055
  • Russia
+7 8

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanolek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 02-Sep-2022 Completed Generating Revenue
4. Secondary Transaction - Private 14-Aug-2019 Completed Generating Revenue
3. Corporate 01-Dec-2016 Completed Generating Revenue
2. Debt - General 21-Feb-2015 $22.9M $168M Completed Generating Revenue
1. Joint Venture 28-Apr-2011 $145M $145M Completed Generating Revenue
To view Nanolek’s complete valuation and funding history, request access »

Nanolek Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanolek Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Epidbiomed Corporation Majority
Merck Corporation Minority
Rusnano Venture Capital Minority
To view Nanolek’s complete investors history, request access »

Nanolek FAQs

  • When was Nanolek founded?

    Nanolek was founded in 2011.

  • Where is Nanolek headquartered?

    Nanolek is headquartered in Moscow, Russia.

  • What is the size of Nanolek?

    Nanolek has 800 total employees.

  • What industry is Nanolek in?

    Nanolek’s primary industry is Drug Discovery.

  • Is Nanolek a private or public company?

    Nanolek is a Private company.

  • What is Nanolek’s current revenue?

    The current revenue for Nanolek is .

  • How much funding has Nanolek raised over time?

    Nanolek has raised $178M.

  • Who are Nanolek’s investors?

    Epidbiomed, Merck, and Rusnano have invested in Nanolek.

  • When was Nanolek acquired?

    Nanolek was acquired on 02-Sep-2022.

  • Who acquired Nanolek?

    Nanolek was acquired by Pharmstandard (Pharmaceuticals).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process